Keith Dionne, Casma CEO (Casma)

Kei­th Dion­ne's Cas­ma lines up a $50M ven­ture round to con­tin­ue the pre­clin­i­cal work on a cel­lu­lar re­cy­cling pro­gram

Two years af­ter launch­ing out of Third Rock’s in­cu­ba­tor, Cas­ma Ther­a­peu­tics has land­ed a $50 mil­lion Se­ries B for pre­clin­i­cal de­vel­op­ment of its mus­cu­lar dy­s­tro­phy and Au­tophagy De­grad­er Plat­form (ADP) pro­grams.

Cas­ma kicked off in 2018 with a $58.5 mil­lion Se­ries A and a staff of ex­perts in au­tophagy, the cell’s “garbage dis­pos­al.” The biotech’s TRPML1 ag­o­nist pro­gram for mus­cu­lar dy­s­tro­phy is ex­pect­ed to hit the clin­ic in 2022, ac­cord­ing to CEO Kei­th Dionne, and the ADP pro­gram is about a year be­hind that.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.